Skip directly to content

Referencias

  1. World Health Organization. Media centre. Cardiovascular diseases (CVDs) Fact sheet N°317. Updated March 2013. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed August 29, 2014
  2. Ferdinand KC, Rodriguez F, Nasser SA, et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med. 2014;4(1):1-11.
  3. Graham G. Population-based approaches to understanding disparities in cardiovascular disease risk in the United States. Int J Gen Med. 2014;7:393-400.
  4. Aiyer AN, Kip KE, Marroquin OC, Mulukutla SR, Edmundowicz D, Reis SE. Racial differences in coronary artery calcification are not attributed to differences in lipoprotein particle sizes: the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) Study. Am Heart J. 2007;153(2):328-334.
  5. Orakzai SH, Orakzai RH, Nasir K, Santos RD, Edmundowicz D, Budoff MJ, Blumenthal RS. Subclinical coronary atherosclerosis: racial profiling is necessary! Am Heart J. 2006;152(5):819-827.
  6. Gadegbeku CA, Lea JP, Jamerson KA. Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am. 2005;89(5):921-933.
  7. Buckalew VM Jr, Freedman BI. Effects of race on albuminuria and risk of cardiovascular and kidney disease. Expert Rev Cardiovasc Ther. 2011;9(2):245-249
  8. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics−−2014 Update: A Report From the American Heart Association. Circulation. 2014;129(3):e28-e292.
  9. World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Geneva, Switzerland: World Health Organization; 2003.
  10. Wu F, Guo Y, Kowal P, et al. Prevalence of major chronic conditions among older Chinese adults: the Study on Global AGEing and adult health (SAGE) wave 1. PLoS One. 2013;8(9):e74176.
  11. Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study. PLoS One. 2014;9(8):e102830.
  12. Kerr AJ, McLachlan A, Furness S, et al. The burden of modifiable cardiovascular risk factors in the coronary care unit by age, ethnicity, and socioeconomic status--PREDICT CVD-9. N Z Med J. 2008;121(1285):20-33.
  13. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY. Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke. 2009;40(6):e415-423.
  14. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780-800.
  15. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
  16. NICE Guidelines 2011. Hypertension in adults: diagnosis and management. August 2011; 1-38
  17. Brenner BM, Cooper ME, de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
  18. de Zeeuw D, Ramjit D, Zhang Zet al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int. 2006;69:1675–1682.
  19. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I–reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979a;242:2562–2571.
  20. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: II–mortality by race-sex and age. JAMA. 1979b;242:2572– 2577.
  21. VA Cooperative 1970. VA Cooperative Study. Effects of treatment on morbidity in hypertension: II–results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143–1152.
  22. VA Cooperative 1967. VA Cooperative Study. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA.1967;202:1028–1034.
  23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Trial to Prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967–1975.
  24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
  25. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595–1608.
  26. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004a;363:2022–2031.
  27. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–2168.
  28. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
  29. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004b;43:1047–1055.
  30. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.